H.C. Wainwright downgraded Mainz Biomed (MYNZ) to Neutral from Buy without a price target after the company presented key data from the eAArly DETECT study, showing 97% sensitivity for colorectal cancer and 82% for advanced precancerous lesions. While the data for the ColoAlert test are encouraging, the company needs to raise a significant amount of capital to complete eAArly DETECT 2 and a pivotal study before regulatory submission, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYNZ:
- Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance
- Mainz Biomed Partners with Thermo Fisher for Cancer Screening
- Mainz Biomed, Thermo Fisher sign collaboration agreement
- Mainz Biomed files to sell 30.77M ordinary shares
- Mainz Biomed Highlights Growth and Innovations for 2025
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
